arrow
M

Morie A. Gertz

Mayo Clinic
H指数:139
被引数:8.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival trends in Waldenström macroglobulinemia and comparison of outcomes with the general United States population

华氏巨球蛋白血症的生存趋势及与全美普通人群结局的比较

Leukemia
IF13.4
2026-11-120
PRE
Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma

细胞衰老的生物标志物及其与多发性骨髓瘤中虚弱、临床结局和生存期的关联

2026-10-300
OAAI
Spatial profiling of extramedullary multiple myeloma demonstrates immune-excluded and suppressive tumor microenvironment

髓外多发性骨髓瘤的空间分布特征显示其存在免疫排斥和抑制性的肿瘤微环境

2026-10-270
OAAI
Subtype specific artificial intelligence modelling of cardiac amyloidosis using echocardiography and electrocardiography

利用超声心动图和心电图进行心脏淀粉样变性亚型特异性人工智能建模

2026-08-280
OA
Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival

1q染色体增益定义了AL淀粉样变性中一种浆细胞占优势的不良风险亚型,其长期生存率较差

2026-08-260
PRE
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients

达雷木单抗治疗的新诊断多发性骨髓瘤患者中缺铁的高发生率

2026-08-210
PRE
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity

预防性地塞米松在绝对淋巴细胞扩增时并不能减轻与免疫效应细胞相关的迟发性神经毒性的风险或无事件生存期

2026-08-100
OA
Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma

移植后可测量残留病灶阴性的预测因素及其对多发性骨髓瘤临床结局的影响

2026-07-290
OA
Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma
Leukemia
IF13.4
2026-07-210
PRE
Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

达拉妥单抗、伊沙佐米和来那度胺联合或不联合地塞米松治疗新诊断骨髓瘤的初始疗法

2026-07-180
OA
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement

中枢神经系统受累的多发性骨髓瘤的临床病程、危险因素和治疗效果

2026-06-260
OA
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma

接受Ciltacabtagene-Autoleucel治疗的复发/难治性多发性骨髓瘤患者的早期治疗失败

2026-06-250
PRE
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

自体干细胞移植治疗多发性骨髓瘤后继发血液系统恶性肿瘤的特征与结局

2026-06-230
OAAI
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

高剂量美法仑联合自体干细胞移植在AL淀粉样变性中远期获益的影响因素

2026-06-070
OAAI
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia

原发性浆细胞白血病患者首次进展后的进展模式与临床结局

2026-06-030
PRE
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype

AL型淀粉样变性接受抗浆细胞疗法后肾脏反应的预测因素:基线血清游离轻链水平和轻链亚型的影响

2026-05-100
PRE
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenström macroglobulinemia

多组学分析揭示MYD88野生型华氏巨球蛋白血症中存在独特的表观遗传特征

2026-05-010
OA